

**Abstracts (Poster Presentation)**

## Development of Transferrin-Conjugated Lipid-Polymer Hybrid Nanoparticles for Alpha-Mangostin Delivery to Targeted Cancer Cells

Intouch Sakpakdeejaroen, Ph.D.\* , Srisopa Ruangnoo, Ph.D.,  
Sumalee Panthong, Ph.D.

### Abstract

**Introduction:** Alpha-mangostin has been reported to play a significant role in inhibiting tumour growth and metastasis. However, its therapeutic potential is limited by its poor aqueous solubility and rapid elimination *in vivo*. To overcome these limitations, we hypothesize that using tumour-targeted delivery system would result in a selective delivery to cancer cells and enhances its therapeutic efficacy.

**Objectives:** To prepare and characterize tumour-targeted delivery entrapping  $\alpha$ -mangostin using transferrin-conjugated lipid-polymer hybrid nanoparticles (Tf-LPHN).

**Methods:** The LPHN entrapping  $\alpha$ -mangostin was prepared by nanoprecipitation method and conjugated with transferrin using the thiol–maleimide ‘click’ reaction. The nanoparticles were optimized and characterized for their physical properties. The *in vitro* therapeutic efficacies were investigated in three cancer cell lines (MCF-7, A549 and B16-F10) that overexpress the transferrin receptors.

**Results:** The optimal formulation of Tf-LPHN had the particle size of  $294.4 \pm 0.7$  nm and zeta potential of  $43.7 \pm 0.6$  mV. The entrapment efficiency of  $\alpha$ -mangostin in both Tf-LPHN and Ctrl-LPHN was relatively high (more than 77%). Tf-LPHN and Ctrl-LPHN exhibited a sustained release of the  $\alpha$ -mangostin at pH 7.4 following an initial burst release (cumulative drug release by about 40% over 72 hours). The entrapment of  $\alpha$ -mangostin in the Tf-LPHN led to an increase in cellular uptake and anti-proliferative activity of  $\alpha$ -mangostin in MCF-7, A549, and B16-F10 cell lines by at least 1.3 to 1.7 times compared with drug solution.

**Conclusions:** These results are promising and support the use of this tumour-targeted delivery system to further improve therapeutic efficacy and tumour specificity of  $\alpha$ -mangostin.

**Keywords:** Alpha-mangostin, Cancer, Lipid-polymer hybrid nanoparticles, Transferrin

**DOI:** <https://doi.org/10.14456/2022s10738>